Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2020.Sep.28

Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development

2020.Sep.28

Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)

2020.Sep.28

New Appointment of Compensation Committee Member

2020.Aug.25

TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866

2020.Aug.25

TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858

2020.Aug.03

Announcement on the change of representative of corporate director

2020.Jul.31

Announcement on resignation of Audit Committee Member

2020.Jul.31

Announcement on resignation of Compensation Committee Member

2020.Jul.31

Announcement on resignation of independent director

2020.Jul.29

TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies

News

Latest News

Events

Latest events